Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Profiling of gut microbiota and plasma metabolites in persons with type 1 diabetes and kidney disease

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. SGLT 2 inhibitors in Type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Hans-Henrik Parving
  • Barry M Brenner
  • John J V McMurray
  • Dick de Zeeuw
  • Steven M Haffner
  • Scott D Solomon
  • Nish Chaturvedi
  • Frederik Persson
  • Maria Nicolaides
  • Alexia Richard
  • Zhihua Xiang
  • Juergen Armbrecht
  • Marc A Pfeffer
  • ALTITUDE Investigators
Vis graf over relationer
Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone.
OriginalsprogEngelsk
TidsskriftJournal of the Renin-Angiotensin-Aldosterone System
Vol/bind13
Udgave nummer3
Sider (fra-til)387-93
Antal sider7
ISSN1470-3203
DOI
StatusUdgivet - 2012

ID: 36594289